Economic Burden of Renal Cell Carcinoma—Part I: An Updated Review
The economic burden of renal cell carcinoma (RCC) had been reported to be significant in a previous review published in 2011.
The objective of this study was to perform an updated review by synthesizing economic studies related to the treatment of RCC that have been published since the previous review.
We performed a literature search in PubMed, EMBASE, and the Cochrane Library, covering English-language studies published between June 2010 and August 2018. We categorized these articles by type of analyses [cost-effectiveness analysis (CEA), cost analysis, and cost of illness (COI)] and treatment setting (cancer status and treatment), discussed findings from these articles, and synthesized information from each article in summary tables.
We identified 52 studies from 2317 abstracts/titles deemed relevant from the initial search, including 21 CEA, 23 cost analysis, and 8 COI studies. For localized RCC, costs were found to be positively associated with the aggressiveness of the local treatment. For metastatic RCC (mRCC), pazopanib was reported to be cost effective in the first-line setting. We also found that the economic burden of RCC has increased over time.
RCC continues to impose a substantial economic burden to the healthcare system. Despite the large number of treatment alternatives now available for advanced RCC, the cost effectiveness and budgetary impact of many new agents remain unknown and warrant greater attention in future research.
The authors thank Dr. Gary Deyter, technical writer from the Department of Health Services Research, The University of Texas MD Anderson Cancer Center, for his editorial contribution.
Data Availability Statement
The data (i.e. Excel file of all abstracts reviewed for this study) generated for the current study are available from the corresponding author upon reasonable request.
Dr. Chien contributed to the study design; acquisition, analysis, and interpretation of the data; and drafting of the manuscript. Drs. Geynisman and Xu contributed to critical review of the manuscripts identified as a result of the search criteria, and commented on the interpretation of the study findings and critical revisions to the manuscript. Dr. Kim contributed to data analysis, information synthesis, and critical reviews/comments. Dr. Shih provided administrative support and senior supervision, and also contributed to the study design; acquisition, analysis, and interpretation of the data; and editing/revising each version of the draft manuscript. All authors approved the final version submitted for publication and agreed to be accountable for all aspects of the work. Dr. Shih acts as the overall guarantor.
Compliance with ethical standards
We acknowledge funding from the China Medical University Hospital (Chien: CRS-106-040) and the National Cancer Institute (Shih: R01 CA207216 and CCSG P30 CA016672).
Conflicts of Interest
Drs. Chien, Geynisman, Xu, Kim, and Shih have no conflicts of interest (either financial or non-financial) to disclose.
- 1.American Cancer Society. Cancer Facts & Figures 2018. Atlanta: American Cancer Society; 2018.Google Scholar
- 3.International Agency for Research on Cancer. Estimated number of incident cases, both sexes, kidney cancer, worldwide in 2012 [cited 17 Apr 2018]. https://gco.iarc.fr/today/online-analysis-table?mode=population&mode_population=continents&population=900&sex=0&cancer=21&type=0&statistic=0&prevalence=0&color_palette=default,%20accessed%202018%2F3%2F3.
- 6.National Comprehensive Cancer Network. NCCN Guidelines with NCCN Evidence Blocks: Clinical Practice Guidelines in Oncology: Kidney Cancer Version 4.2018. 2018. https://www.nccn.org/professionals/physician_gls/pdf/kidney_blocks.pdf. Accessed 1 May 2018.
- 7.National Cancer Institute. Drugs Approved for Kidney (Renal Cell) Cancer. 2018. https://www.cancer.gov/about-cancer/treatment/drugs/kidney. Accessed 10 Apr 2018.
- 10.Health Information Research Unit. Search Filters for MEDLINE in Ovid Syntax and the PubMed translation. https://hiru.mcmaster.ca/hiru/hiru_hedges_medline_strategies.aspx. Accessed 1 Feb 2018.
- 12.Bureau of Labor Statistics. CPI Databases. https://www.bls.gov/cpi/data.htm. Accessed 10 Mar 2018.
- 13.International Monetary Fund. World Economic Outlook Database. 2017. http://www.imf.org/external/pubs/ft/weo/2017/02/weodata/download.aspx. Accessed 30 Apr 2018.
- 16.Petrou P. A systematic review of economic evaluations of tyrosine kinase inhibitors of vascular endothelial growth factor receptors, mammalian target of rapamycin inhibitors and programmed death-1 inhibitors in metastatic renal cell cancer. Expert Rev Pharmacoecon Outcomes Res. 2018;18(3):255–65.CrossRefGoogle Scholar
- 28.Paz-Ares L, del Muro JG, Grande E, Diaz S. A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System. J Clin Pharm Ther. 2010;35(4):429–38.PubMedGoogle Scholar
- 30.Edwards SJ, Wakefield V, Cain P, Karner C, Kew K, Bacelar M, et al. Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess. 2018;22(6):1–278.CrossRefGoogle Scholar
- 37.Meng J, Lister J, Vataire AL, Casciano R, Dinet J. Cost-effectiveness comparison of cabozantinib with everolimus, axitinib, and nivolumab in the treatment of advanced renal cell carcinoma following the failure of prior therapy in England. Clinicoecon Outcomes Res. 2018;10:243–50.CrossRefGoogle Scholar
- 38.Swallow E, Messali A, Ghate S, McDonald E, Duchesneau E, Perez JR. The additional costs per month of progression-free survival and overall survival: an economic model comparing everolimus with cabozantinib, nivolumab, and axitinib for second-line treatment of metastatic renal cell carcinoma. J Manag Care Spec Pharm. 2018;24(4):335–43.PubMedGoogle Scholar
- 41.Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8 Suppl):IV-3–-18.Google Scholar
- 52.Hansen RN, Hackshaw MD, Nagar SP, Arondekar B, Deen KC, Sullivan SD, et al. Health care costs among renal cancer patients using pazopanib and sunitinib. J Manag Care Spec Pharm. 2015;21(1):pp. 37–44, a-d.Google Scholar
- 56.Vogelzang NJ, Pal SK, Ghate SR, Li N, Swallow E, Peeples M, et al. Real-world economic outcomes during time on treatment among patients who initiated sunitinib or pazopanib as first targeted therapy for advanced renal cell carcinoma: a retrospective analysis of medicare claims data. J Manag Care Spec Pharm. 2018;24(6):525–33.PubMedGoogle Scholar
- 68.Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care. 2002;40(8 Suppl):IV-104–17.Google Scholar
- 70.Ballali S, Chiffi D, Trojniak MP, Gregori D. Agreement tE-VRP. Economic impact of sunitinib and sorafenib use in metastatic renal cell carcinoma treatment in Veneto region. Italy. Open Pharmacol J. 2013;7(Suppl 1):M2:2–8.Google Scholar
- 71.Maroun R, Fleury L, Nachbaur G, Maunoury F, Vanhille JL, Durand-Zaleski I. Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database. Curr Med Res Opin. 2017;33(10):1755–62.CrossRefGoogle Scholar